Cognition Therapeutics, Inc. Cash and Restricted Cash
Cognition Therapeutics, Inc. (CGTX) had Cash and Restricted Cash of $34.76 million as of 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-07
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $34.76M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $31.23M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $37.00M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $39.82M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2026-06-30 | $34.76M 10-Q · filed 2026-08-07 |
| 2026-03-31 | $31.23M 10-Q · filed 2026-05-08 |
| 2025-12-31 | $37.00M 10-Q · filed 2026-08-07 |
| 2025-09-30 | $39.82M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $11.56M 10-Q · filed 2026-08-07 |
| 2025-03-31 | $16.43M 10-Q · filed 2026-05-08 |
| 2024-12-31 | $25.01M 10-Q · filed 2026-08-07 |
| 2024-09-30 | $22.01M 10-Q · filed 2025-11-06 |
| 2024-06-30 | $28.53M 10-Q · filed 2025-08-07 |
| 2024-03-31 | $34.67M 10-Q · filed 2025-05-07 |
| 2023-12-31 | $29.92M 10-K · filed 2026-03-26 |
| 2023-09-30 | $32.97M 10-Q · filed 2024-11-13 |
| 2023-06-30 | $37.19M 10-Q · filed 2024-08-08 |
| 2023-03-31 | $38.81M 10-Q · filed 2024-05-07 |
| 2022-12-31 | $41.56M 10-K · filed 2025-03-20 |
| 2022-09-30 | $46.61M 10-Q · filed 2023-11-02 |
| 2022-06-30 | $45.77M 10-Q · filed 2023-08-08 |
| 2022-03-31 | $51.51M 10-Q · filed 2023-05-04 |
| 2021-12-31 | $54.72M 10-K · filed 2024-03-26 |
| 2021-09-30 | $8.31M 10-Q · filed 2022-11-14 |
| 2021-06-30 | $11.30M 10-Q · filed 2022-08-09 |
| 2021-03-31 | $13.37M 10-Q · filed 2022-05-11 |
| 2020-12-31 | $5.19M 10-K · filed 2023-03-23 |
| 2020-09-30 | $5.24M 10-Q · filed 2021-11-17 |
| 2019-12-31 | $2.89M 10-K · filed 2022-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |